SAF-301

N/A

Report date: 2024/07/24 20:00:37

Base Information

Drug NameSAF-301
Drug Alias NameSAF-301
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionGene transference
TargetsN-sulphoglucosamine sulphohydrolase
Therapy Area/IndicationsMucopolysaccharidosis III
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesLysogeneSarepta Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesLysogene
Active IndicationsN/A
Inactive IndicationsMucopolysaccharidosis III

Other Information

ATC CodeN/A
Related LinksN/A